文献速递瓣膜外科

心脏移植后即刻三尖瓣反流与远期结局

Tricuspid Valve Regurgitation Immediately After Heart Transplant and Long-Term Outcomes.
PubMed 文献 · Ann Thorac Surg · 2018-12-05

该回顾性队列研究纳入542例心脏移植患者,术中脱离体外循环后评估三尖瓣反流(TR)程度。21%患者存在显著TR,与术后最高血肌酐升高、住院时间延长及校正生存率降低相关;但91%的显著TR在移植后1年内消退,仅1%患者需延迟三尖瓣修复。

要点

  • 心脏移植后即刻显著TR发生率为21%,多数在1年内自行消退。
  • 显著TR与术后肾功能损害、住院时间延长及校正生存率降低相关。
  • 仅1%患者因显著TR需延迟三尖瓣修复,早期手术修复策略尚待明确。

核心结论

  • 心脏移植后即刻显著TR常见,与早期并发症和校正生存率降低相关,但多数在1年内消退。

研究设计与样本

  • 回顾性队列研究,纳入2000年1月至2012年6月Duke大学医学中心542例原位心脏移植患者,排除同期TR修复、多器官移植或再次移植者。
  • 术中脱离体外循环后评估TR,分为无/轻度(不显著)与中/重度(显著),随访TR分级变化及结局。

主要发现

  • 114例(21%)脱离体外循环后存在显著TR,术前受体肺血管阻力无显著差异。
  • 显著TR组术后最高血肌酐中位数2.2 mg/dL(IQR 1.5-3.2)vs 1.8 mg/dL(IQR 1.4-2.6),p=0.008。
  • 显著TR组术后住院时间中位数12天(IQR 9-21)vs 10天(IQR 8-14),p<0.001。
  • 显著TR与校正生存率降低相关;91%的显著TR在移植后1年内转为不显著。
  • 6例(1%)显著TR患者在随访期间因显著TR行延迟三尖瓣修复。

临床怎么用

  • 心脏移植术中脱离体外循环后应评估TR程度,显著TR者需加强术后肾功能和住院时间管理。
  • 多数显著TR可自行消退,随访中需监测TR变化,仅少数需延迟手术修复。

局限性

  • 回顾性单中心研究,样本来自特定时间段,结论外推需谨慎。
  • 显著TR的随访与治疗最优方案尚未定义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tricuspid valve regurgitation (TR) is a common finding immediately after cardiac transplantation. However, there is a scarcity of data regarding its implication if left untreated on long-term outcomes and the role of early surgical repair. METHODS: We retrospectively reviewed the Duke University Medical Center transplant database from January 2000 to June 2012 and identified 542 patients who underwent orthotropic heart transplantation. Patients were excluded if they underwent surgical repair for TR during the transplant or if the transplant was part of a multiorgan transplant or redo heart transplantation. TR was assessed intraoperatively after weaning from cardiopulmonary bypass. Independent variables were grade of TR and changes in TR grade during follow-up. TR grades were classified as insignificant (none or mild) versus significant (moderate or severe). Survival and need for posttransplant valve repair during follow-up were assessed. RESULTS: Significant TR was detected in 114 patients (21%) after weaning from cardiopulmonary bypass, with no significant difference in preoperative recipient pulmonary vascular resistance. Significant TR was associated with increased maximum postoperative plasma creatinine (median [interquartile range], 2.2 [1.5 to 3.2] mg/dL vs 1.8 [1.4 to 2.6] mg/dL, p = 0.008), prolonged postoperative stay (median [interquartile range], 12 [9 to 21] days vs 10 [8 to 14] days; p < 0.001), and decreased adjusted survival. Significant TR regressed to insignificant in 91% of recipients by 1 year after transplant. Six recipients (1%) who had significant TR after cardiopulmonary bypass underwent delayed tricuspid valve repair for significant TR during follow-up. CONCLUSIONS: Significant TR is a common finding immediately after transplant and is associated with early morbidity and reduced adjusted survival. Most significant TR resolves by 1 year after transplant. Optimal algorithms for follow-up and treatment of significant TR after heart transplantation need to be defined.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Bishawi M, Zanotti G, Shaw L, et al. Tricuspid Valve Regurgitation Immediately After Heart Transplant and Long-Term Outcomes. Ann Thorac Surg. 2018. PMID: 30529215. doi:10.1016/j.athoracsur.2018.10.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。